Marinomed: Anti-viral medication from Vienna to receive Houska Award worth 150,000 euros

Name: _pk_id Used for : Is used to store an unique ID for each user Duration : 13 Months
Name: &nbsp;_pk_ses, _pk_cvar, _pkhsr Used for :&nbsp;Session cookies that store temporary data Duration :&nbsp;30 minutes
Name: mtm_consent Used for : Stores cookie preferences Duration : 30 years

Marinomed develops therapies against respiratory diseases using its innovative antiviral respiratory technology platform, MAVIREX. Its successful products won over the jury that selected the winners of the Houska Award, which is Austria’s largest privately funded research award granted by the B&C Privatstiftung.

Sorry, this entry is only available in German!

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.

Marinomed: Anti-viral medication from Vienna to receive Houska Award worth 150,000 euros

Uni Vienna: Giant Viruses Infect Deadly Parasite

BMAW: Kocher: Österreich auf dem Weg zur höchsten Forschungsquote in der EU

Österreich investiert 2024 so viel wie nie zuvor in Forschung: Forschungsquote steigt auf 3,34%